Glass House Brands (GLAS) Gains from Investment Securities (2021 - 2026)
Glass House Brands (GLAS) posted quarterly Gains from Investment Securities of -$409000.0 for Q1 2026, down 123.6% year-over-year from $1.7 million in Q1 2025, and down 1236.11% quarter-over-quarter from $36000.0 in Q3 2025.
Glass House Brands (GLAS) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Gains from Investment Securities for 6 consecutive years, with -$409000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 123.6% year-over-year to -$409000.0; the TTM figure through Mar 2026 stood at $1.7 million (up 60.92% YoY), while the FY2022 annual figure was $186107.0, down 99.47% from the prior year.
- Gains from Investment Securities slipped to -$409000.0 in Q1 2026 per GLAS's latest filing, from $36000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.7 million in Q1 2025 and bottomed at -$539000.0 in Q3 2024.
- Historically, Gains from Investment Securities has averaged $98092.2 across 5 years, with a median of -$22500.0 in 2023.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities plunged 769.23% — and 2025, when it surged 1633.63%.
- Glass House Brands' Gains from Investment Securities stood at $586453.0 in 2022, then sank by 102.22% to -$13000.0 in 2023, then slumped by 4046.15% to -$539000.0 in 2024, then jumped by 106.68% to $36000.0 in 2025, then sank by 1236.11% to -$409000.0 in 2026.
- Business Quant data shows GLAS's Gains from Investment Securities at -$409000.0 in Q1 2026, $36000.0 in Q3 2025, and $328000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -409,000.00 |
| Mar 31, 2026 | -409,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 328,000.00 |
| Jun 30, 2025 | 328,000.00 |
| Mar 31, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Sep 30, 2024 | -539,000.00 |
| Sep 30, 2024 | -539,000.00 |
| Jun 30, 2024 | -32,000.00 |
| Jun 30, 2024 | -32,000.00 |
| Mar 31, 2024 | -113,000.00 |
| Mar 31, 2024 | -113,000.00 |
| Mar 31, 2023 | -13,000.00 |
| Mar 31, 2023 | -13,000.00 |
| Dec 31, 2022 | 586,453.00 |
| Dec 31, 2022 | 586,453.00 |
| Sep 30, 2022 | -300,552.00 |
| Sep 30, 2022 | -300,552.00 |